On September 29th, 2025, the US Food and Drug Administration (FDA) issued two letters reversing its previous position on beta-nicotinamide mononucleotide (NMN), confirming that the ingredient is lawful for use in dietary supplements. This decision overturns the agency's earlier interpretation that excluded NMN under the drug preclusion clause of the Food, Drug and Cosmetic Act (FD&C).

The policy shift represents a notable change in the FDA's regulatory approach to NMN, an ingredient that has been the subject of considerable debate within the supplement industry.

The Drug Preclusion Clause Analysis

The FDA's reversal centers on its analysis of the "race to market" provision, which determines whether a substance can be sold as a supplement if it is also being investigated as a pharmaceutical drug. The agency concluded that sufficient evidence exists demonstrating NMN was marketed as a dietary supplement in the United States before receiving authorization for drug investigation.

A critical element in the FDA's decision was the recognition that NMN is a naturally occurring molecule produced by the human body as part of the NAD+ biosynthesis pathway. This biological characteristic informed the agency's classification of NMN as appropriate for dietary supplement use rather than exclusive pharmaceutical application.

The drug preclusion clause has historically created regulatory uncertainty for ingredients that undergo both supplement marketing and pharmaceutical investigation. The FDA's interpretation of when an ingredient was "first marketed" versus when it entered "substantial clinical investigation" has been a source of ongoing debate within the industry.

Industry Advocacy and Response

The decision follows years of advocacy efforts from multiple industry organizations, including the Natural Products Association (NPA), Alliance for Natural Health USA, and the Council for Responsible Nutrition. These groups filed petitions requesting the FDA reconsider its position on NMN's regulatory status.

While the FDA granted portions of these petitions, the agency did not provide clarification on what constitutes "substantial" clinical investigation. This omission leaves questions unresolved regarding how the drug preclusion clause will be applied to other ingredients in the future.

Bryan Nettles, CEO of Renue by Science, characterized the decision as "a historic day for both the supplement industry and the consumers we serve." He stated that the reversal "confirms what we've known all along, that NMN is a safe, effective and lawful supplement for promoting healthy ageing and vitality."

Industry representatives have expressed differing perspectives on the comprehensiveness of the FDA's guidance. Some view the decision as a significant victory for consumer access to supplements, while others note that the agency continues to provide limited guidance on interpreting the drug preclusion clause for future ingredients.

Implications for Pricing and Access

Industry advocates have raised concerns about the impact of regulatory classification on consumer costs. The reversal has been framed by some as protecting consumers from what they describe as inflated pharmaceutical pricing by maintaining NMN's availability in the supplement market.

The distinction between pharmaceutical and supplement classification carries significant implications for pricing structures, distribution channels, and accessibility. Pharmaceutical products typically undergo more extensive clinical trials and regulatory review processes, which can result in higher costs passed to consumers.

However, the relationship between regulatory classification and pricing is complex, involving factors such as manufacturing standards, testing requirements, distribution networks, and market competition that extend beyond the initial regulatory designation.

Remaining Regulatory Uncertainties

Despite the FDA's decision on NMN, questions remain about the agency's broader approach to the drug preclusion clause. The lack of specific guidance on what constitutes "substantial" clinical investigation means companies developing new ingredients face uncertainty about potential regulatory challenges.

The threshold for demonstrating an ingredient was marketed before substantial drug investigation began remains unclear. Industry stakeholders have requested more precise criteria to help companies navigate this regulatory requirement proactively.

The FDA's case-by-case approach to these determinations may provide flexibility but creates challenges for companies seeking predictability in product development and marketing decisions.

Future Industry Considerations

The NMN decision may influence how companies approach documenting the marketing history of supplements and the timing of such efforts relative to drug investigations. Maintaining comprehensive records of marketing activities could become increasingly important for establishing regulatory compliance.

The reversal also highlights ongoing tensions between pharmaceutical development and the marketing of dietary supplements using the same compounds. As research into longevity and age-related health continues, more ingredients may face similar regulatory questions about appropriate classification.

Industry observers note that the decision could impact innovation pathways, investment decisions, and research priorities within the supplement sector, although the full implications may take some time to materialize.

Navigate Supplement Industry Compliance with Confidence

Regulatory changes in the nutraceutical industry require proactive compliance management. Qredible's Q-Trust platform provides comprehensive quality management solutions designed specifically for highly regulated industries. Schedule a discovery call to learn how our technology can help your business maintain compliance and build trust in an evolving regulatory environment.